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Summary 
Contributions to this column and to other public
columns a year ago addressed the availability of medici-
nal products in Finland. It transpired that within ten
years medicines authorised for marketing had, in fact,
fallen from having been almost 100% available on the
market to 77% of all valid marketing authorisations.
The situation of medicinal products within the EU cen-
tralised approval system was found to be even worse.
Improvements have been made in monitoring the
availability of medicinal products by the NAM in Fin-
land. According to the information from last August
(see p. 62 the ex tempore column), however, the situa-
tion of availability has in fact become worse. Over a
third of the medicinal products with valid marketing au-
thorisation are not actually for sale in Finland. The situ-
ation is partly explained by the fact that during the last
couple of years the NAM may have processed a great
number of marketing authorisation applications within
the stipulated time limit for processing, and that, conse-
quently, the applicants have not yet managed to bring
their products on to the market. Nevertheless, the list of
“medicinal products not available” unfortunately also
contains a large number of items from even earlier
years.
There are many reasons for the prevailing circum-
stances, not the least important one of which is the fact
that the EU allows marketing authorisations to be ap-
plied for without any obligation for the applicant to en-
sure the availability of the medicinal product on the
market. Member states with smaller pharmaceutical
markets are particularly those which suffer most. Simi-
larly, countries with well operating authorisation proce-
dures in place also suffer, since that makes it attractive
for the marketing authorisation applicants to use the au-
thorisation approved in such a country only as a step-
ping stone towards approval in other countries.
It is therefore excellent news for the pharmaceutical
markets and authorisation procedures in Finland and
the EU that the EU Directive relating to medicinal prod-
ucts for human use has been amended by a new Direc-
tive with regulations with the following contents, for ex-
ample1:  
“Any authorisation which within three years of
its granting is not followed by the actual placing on
the market of the authorised product in the authoris-
ing Member State shall cease to be valid.
When an authorised product previously placed on
the market in the authorising Member State is no 
longer actually present on the market for a period of
three consecutive years, the authorisation for that
product shall cease to be valid.”
These regulations will be included in the Medicines
Act and will come into force in Finland by the 30th of
October 2005. According to the statements emanating
from within the pharmaceutical industry itself, the pur-
pose of applying for a marketing authorisation is to
make the medicinal product actually available on the
market.
The new regulations are helpful to the pharmaceuti-
cal industry and the authorities insofar as unnecessary
preparations and processing of applications, the duties
associated with the maintenance of marketing authorisa-
tions, and the costs associated therewith, can be avoided
with some advance consideration. An authorisation sys-
tem should have a purpose which is fulfilled; this is an
old principle and one even endorsed by the EU itself.
1) Directive 2004/27/EC of the European Parliament and of the
Council [Article 24(4) and 24(5)]; OJ L 136, 30.4.2004, p. 43.
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As in other developed countries, the
majority of cases of diarrhoea in
Finland are caused by a virus; bacte-
rial diarrhoea is rare (2). Antibiotics
are therefore seldom of use in the
treatment. Dehydration is the most
severe complication of diarrhoea;
treatment of diarrhoea is therefore
aimed at the prevention and treat-
ment of dehydration. Fluid therapy
is given independently of the causes
of the diarrhoea. Oral rehydration
solution, which has been in use for
over 30 years, has revolutionised the
treatment of diarrhoea and saved
millions of children world-wide. The
introduction of the oral rehydration
solution in Finnish hospitals, and
the uninterrupted feeding practices
adopted in the 1980’s, together with
good treatment results, reduced the
hospitalisation periods by one day
during 1986–1995 (1).
Concern about the inadequate
treatment of diarrhoea in children
has been expressed in many devel-
oped countries. In England the treat-
ment of more than a third of the
children has been based on inade-
quate instructions given by the fami-
ly doctor for the treatment of diar-
rhoea (3). In the USA, over half of
paediatricians did not follow the in-
structions of the AAP (American
Academy of Pediatrics) on the use of
the oral rehydration solution and
uninterrupted feeding practices (4).
In the UK, over 50% of pharmacists
gave incorrect instructions to par-
ents about the treatment of diar-
rhoea in their children by recom-
mending antidiarrhoeal agents and
advising mothers to stop breastfeed-
ing for the duration of the diarrhoea
(5).
Subsequently, a retrospective sur-
vey of childhood diarrhoea and
home treatment practices was car-
ried out in Finland in 1996 based on
the catchment area of Espoo and its
well-baby and maternity clinics. A
total of 1,726 mothers and their
2,230 children under the age of 5
were interviewed. The survey
showed that 37% of the children
were given a rehydration solution
(70% in fact, if the disorder was se-
vere enough for the child to be hos-
pitalised), 55% of the children were
offered normal or greater than nor-
mal size diets, and 7% of the chil-
dren were put on a fasting diet dur-
ing the diarrhoea. 74% of the chil-
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Summary 
Acute diarrhoea still remains among the most common diseases in children in Finland resulting in
around 3,500 hospitalisation periods each year (1). There has been a noticeable reduction in the
occurrence of fatal diarrhoea in Finland during the last decades. Nevertheless, as late as between
1986 and 1995 nine children originally in good health died of diarrhoea in Finland (1). Over half
of the deaths occurred at home or on the way to the hospital, underlining the importance of effec-
tive care at home and correct timing in seeking help.
Main principles in  the treat-
ment of  acute chi ldhood
diarrhoea
• Fluid therapy or prevention of
development of dehydration and
correction of any dehydration
present
• Early feeding
• Use of probiotics 
• Avoidance of antidiarrhoeal
drugs
Table 1. Change of home treatment practices of acute pediatric diarrhoea in Fin-
land (Isolauri et al. 1989, Rautanen et al. 1998)
1978 1987 1996
Preadmission of ORS use rate 3 % 29 % 70 %
Use  of antidiarrhoeal drugs 11 % 3 % 0.7 %
Fasting 67 % 53 % 7 %
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dren who were being breastfed were
offered breast milk more often than
usual throughout the diarrhoea. The
figures show that the home treat-
ment practices are not optimal, but
a distinct improvement has been
made compared with 1978 and
1987 (Table 1) (6, 7). Not all moth-
ers are aware of the importance of
the oral rehydration solution and
continued feeding. Instructions for
the treatment of diarrhoea given by
health centres, well-baby and mater-
nity clinics and pharmacies are
therefore of paramount importance.
Fluid therapy
The prevention of dehydration
should be started immediately at the
onset of diarrhoea. The parents
should offer their child greater
amounts of fluid than normal (8). If
the child is still being breastfed, the
number of feeds should be in-
creased, as breast milk is an excel-
lent rehydration solution (8, 9). The
best product to prevent dehydration
is the oral rehydration solution
available from pharmacies; water
should be offered freely along with
it. At the stage of prevention, mild
juices, milk and soup are also ap-
propriate drinks. Beverages with
high sugar contents such as soft
drinks should be avoided. Due to
their high sugar contents these
drinks have no rehydration proper-
ties; they cause osmotic diarrhoea
instead and promote the develop-
ment of dehydration. For the pre-
vention of dehydration, the oral re-
hydration solution is administered at
a dose of 1/2 dl per each diarrhoeal
stool in children under 2 years of
age, and about 1 dl per each diar-
rhoeal stool in children over 2 years
of age (8). If the child is showing
signs of dehydration, its degree
should be established depending on
the weight loss or clinical findings.
The loss is overcompensated by giv-
ing 4/3 of estimated fluid deficiency
within the subsequent 6 hours (10).
The administration of plenty of 
fluids is continued thereafter similar-
ly to the prophylactic practices of
dehydration. The average duration
of diarrhoea is 4.8 days (6); and the
administration of plenty of fluids
should continue throughout the di-
arrhoea.
In mild and moderate dehydra-
tion, fluid therapy with oral rehy-
dration solution has been shown in
several studies to be at least as effec-
tive as intravenous fluid therapy, or
even superior, since the duration of
diarrhoea in children on oral rehy-
dration therapy is shorter and their
weight gain is superior to those on
intravenous fluid therapy (11, 12).
Severe dehydration requires intra-
venous fluid therapy. Even then, oral
fluid therapy should be introduced
as quickly as possible after recovery
from dehydration (8).
Consulting a doctor is recom-
mended if the child exhibits distinct
signs of dehydration, or the child is
very restless or exhausted, diarrhoea
and/or vomiting occurs very fre-
quently, or blood is present in the
stools. Diarrhoea in infants under 6
months of age calls for prompt con-
sultation with a doctor because of
the risk of rapid development of de-
hydration.
Early feeding
Fasting was a common practice and
part of the treatment of diarrhoea
for a long time also in Finland. Sev-
eral clinical studies have shown re-
duced duration of the diarrhoea and
improved weight gain, once the chil-
dren had started receiving full diets
appropriate for their age immediate-
ly after the initial fluid therapy. Fast-
ing and gradual reintroduction of
food will lead to prolonged diar-
rhoea, impaired weight increase and
damage to the mucous membrane
(13, 14). Following recovery from
dehydration, the child should be giv-
en energy-rich and easily digested
food even more frequently than usu-
al (8). Breastfeeding should also be
continued throughout the recovery
period (8, 9). Replacement products
or milk products should not be di-
luted, and there is no need to put
the child on to a milk-free diet (14,
15).
Use of probiotics
The use of probiotics, or live micro-
organisms improving the wellbeing
of the intestine, have been found to
shorten the duration of acute diar-
rhoea (16, 17, 18, 19). Products
containing Lactobacilli enhance the
immune response of the intestine,
they produce agents inhibiting bac-
terial growth and they interfere with
the attachment of pathogens to the
mucous membrane (16, 17, 20, 21).
Probiotic therapy introduced at an
early stage reduces the duration of
diarrhoea by about a day. The rec-
ommended dosage consists of one
tablet or a dose of Lactobacillus in
powder form, or, alternatively, one
dose of a sour milk product twice
daily throughout the diarrhoea.
The probiotic therapy has been
rapidly adopted by Finnish mothers.
In the survey carried out in well-ba-
by and maternal clinics in Espoo
44% of the children had received a
probiotic product during the diar-
rhoea.
Avoidance of antidiarrhoeal
drugs
Antidiarrhoeal drugs are not a reme-
dy for the actual complication of di-
arrhoea which is dehydration. Anti-
motility drugs (loperamide, opiates)
depress intestinal peristalsis thus re-
ducing the frequency of stools pas-
sage. They do not prevent the secre-
tion of diarrhoeal stools or the de-
velopment of dehydration. They
make the assessment of dehydration
difficult, because there is no weight
reduction and the actual amount of
stool is not visible. They may cause
side-effects such as paralytic ileus
and CNS symptoms which interfere
with successful fluid therapy. These
drugs should not be used in chil-
dren, and their use even in adults
has potential benefits only in tempo-
rary use, e.g. making a flight jour-
ney home possible. Adsorbing medi-
cinal substances such as medicinal
charcoal or bismuth are considered
to adsorb the bacterial toxins which
induce diarrhoea. In practice, the ef-
fect of these drugs is insignificant
and they may be described as “stool
cosmetics”. They hardly cause any
side-effects, but they may give a
false impression of safety, result in
negligence of fluid therapy and in-
crease the price of treatment (22,
23).
The use of antidiarrhoeal drugs
has never been a big problem (Table
1) in Finland compared with several
southern European countries and
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developing countries where the use
of symptomatic drugs may be so
high as to exceed 50%. In the sur-
vey carried out well-baby and ma-
ternity clinic in Espoo the use of
symptomatic drugs amounted to on-
ly 0.7% (3). Two thirds of these
drugs were obtained from abroad.
Conclusion
The practices with regard to the
treatment of childhood diarrhoeas in
hospitals and at home have im-
proved and largely follow the treat-
ment recommendations of WHO.
Information and awareness about
the oral rehydration solution should
be disseminated further, since its use
should be close to 100% in acute di-
arrhoeal disorders both in the home
and in hospital situations.
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A total of 273 new clinical drug
trials were notified to the NAM in
2003. Documents associated with
clinical drug trials submitted to the
NAM fall within the category of
business secrets and professional se-
crecy (the Act on the Openness of
Government Activities 621/1999).
The processing of the notifications
involves storing the key data in the
data management system of the
NAM. The NAM then uses the in-
formation contained in the database
for its supervisory duties relative to
clinical drug trials, in accordance
with the Medicines Act and for the
managerial and statistical compiling
purposes relating to the trial reports. 
In 2003, the pharmaceutical in-
dustry sponsored 187 (68%) of the
new trials notified, whereas 86 trials
(32%) were to be carried out with-
out outside financing. Additional in-
formation was requested by the
NAM on 127 trials (47%). Com-
pared with previous years, the num-
ber of requests for additional infor-
mation has remained fairly un-
changed.
Number of trials
The number of drug trials notified
to the NAM has varied between 263
and 313 during 1994–2003 (Fig. 1).
A clear majority of notifications in
2003 were made on trials at phase
III, i.e. 41% of the total number
(113 in all). The proportion of
phase I trials was the smallest, i.e.
11% of the reports (30 in all). The
number of phase II trials was 72
(26%), and of phase IV trials there
were 58 in all (21%). The number
of reports of phase II and IV trials
received was slightly higher than the
year before, but the variations were
relatively small.
Of the trials notified during
2003, 7%, or 20 in number, were
cancelled before the start. Up until
the point of writing this survey, 6
trials had been discontinued on the
initiative of the sponsor of the trial.
Reasons for the discontinuation in-
clude a higher number of adverse
drug reactions than expected, lack
of efficacy of the trial product and
redirection of the sponsor’s re-
sources towards other projects. One
trial was also prohibited by the
NAM due to insufficient data sub-
mitted in the notification regarding
the trial drug used in safety studies
in animals and relating to the phar-
maceutical and – chemical proper-
ties of the trial product.
The trial notification should con-
tain an estimate of the number of
trial subjects. According to the prior
information received, trials notified
in 2003 will have a total of 10,763
subjects participating. 
A review according to ATC cate-
gories (Fig. 2) reveals that the
largest number of trials were report-
ed on antineoplastics and im-
munomodulating agents (19.5 %).
The second largest group consisted
of drugs acting on the nervous sys-
tem (16.0 %), followed by cardio-
vascular drugs (9.5 %), musculo-
skeletal system drugs (9.2 %) and
drugs used in diseases involving the
blood and blood-forming organs
(7.9 %).
Trial products
A review of the trial products in-
volved shows that the majority of
products were conventional syntheti-
cally manufactured medicines. Ac-
cording to the classification of the
Agency, 52% of the trial notifica-
tions (142 in total) involved an al-
ready known medicinal substance
Tiina Seppä
SENIOR RESEARCHER, PHD (PHARM)
National Agency for Medicines
Clinical drug trials notified to the National
Agency for Medicines in 2003
Fig.  1 .  Numbers of  t r ial  noti f icat ions  and complementary and addit ion-
al  reviews requested by the NAM. Prior  to 1997,  stat ist ics  of  addit ional
reviews requested in associat ion with prel iminary technical  examina-
t ions were not  recorded.
Summary 
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with a marketing authorisation ei-
ther in Finland or some other coun-
try. A total of 21 notifications (8%)
involved a pharmaceutical innova-
tion making use of biotechnology.
Only one trial notified in 2003 in-
volved gene therapy.
Deficiencies discovered in the tri-
al notifications 
On receipt of the trial notification ,
the National Agency for Medicines
may request additional information
while the preliminary administrative
review is carried out. Once the ex-
pert reviews are in, additional infor-
mation may still be requested by the
Agency as necessary.
The majority of the deficiencies
detected in the preliminary technical
review of the trial notifications in-
volved the documentation on the
manufacture and quality of the trial
drugs. Documents on products with-
out a marketing authorisation should
include the data on their pharmaceu-
tical and chemical properties, which
were missing in 21 cases (8%). A re-
view of the manufacture of the trial
drug according to good manufactur-
ing practices (a pharmaceutical man-
ufacturing authorisation or a GMP
certificate issued by the authorities)
was missing in 24 cases (9%). Other
deficiencies detected in the prelimi-
nary reviews include, for example,
irregularities in the supplying of the
trial drug to trial centres and in re-
mitting the trial fee to the Agency,
and the omission of details of the
sponsor’s agent or contact person.
Two notifications contained no trial
protocol at all. The processing of the
notifications in these cases will not
be started until they have been com-
pleted appropriately and all neces-
sary information supplied.
The most common cause for re-
questing additional information after
the completion of an expert review
was an inadequate patient informa-
tion leaflet or consent form. In 2003,
requests were made for the patient
information leaflet for 79 reports
(29%) to be completed or corrected,
while for 22 trial reports (8%) the
consent form had to be completed or
corrected. Stipulations for the con-
tents of the consent form are found
in the Medical Research Decree
(986/1999). The deficiencies detected
by the NAM have mostly involved
technical details referred to in the
Decree. A suggestion has often also
been made by the Agency to include
a reference in the consent form re-
garding the right of a foreign drug
authority to examine the patient
documents. The NAM in Finland has
this right in accordance with the
Medicines Act, but if the intention is
to give the examination right to a
foreign authority as well, a special
reference needs to be made in the
consent form.
Further common causes for re-
questing additional information in
the notifications of 2003 included is-
sues relating to the manufacture and
quality of the trial product in 38 re-
ports (14%) and issues relating to
patient safety in 28 reports (10%).
The requests for additional informa-
tion on patient safety issues mostly
deal with the performance during the
trial of laboratory tests aimed at en-
suring the safe use of the product
(e.g. ECG, blood count, monitoring
of liver and kidney function). The
more rare requests for additional in-
formation dealt with the trial setting
(13 requests, or 5%) or the statistical
processing of the results (3 requests,
or 1%).
Reviews of trial results
The investigator and the sponsor are
obliged to submit a review of the tri-
al results to the Agency within a year
following the end of the trial. This
was previously stipulated in the
Agency’s regulation on clinical trials,
but after a reform of the national
legislation following the enforcement
of the EU Clinical Trials Directive,
the submission of reviews is now
stipulated in an Act of the Law (Sec-
tion 10h of the Medical Research
Act). Reviews of results from 254
trials were submitted to the Agency
in 2003. It is still the case that about
50% of investigators and sponsors
do not send the requested reviews to
the Agency until after receiving a
written reminder. As the obligation
to submit a review is now included
in an Act of the Law, it is expected
that researchers in future will re-
member to make a review of their
trial results available to the authori-
ties without a special request from
the Agency.Fig.  2.  Divis ion of  the tr ial  drugs into main ATC categories 2003
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The medical treatment of psychiatric
conditions has over the past decade
or more been considerably re-
formed, and improved tolerability
and efficacy have been attained with
the new alternatives of medical
treatment for psychiatric disorders.
Prior to launching on to the market,
a new drug will need to undergo ex-
tensive clinical drug trials with the
aim of surveying its efficacy, safety,
tolerability and appropriate dosage
range. In addition to using groups of
patients receiving medical treatment
with the active agent, these trials al-
so use groups of patients receiving a
placebo lacking any pharmacologi-
cal effect. Nonetheless, not all clini-
cal drug trials, e.g. trials surveying
the pharmacokinetic properties and
potential interactions, use a placebo
group.
The first placebo-controlled clini-
cal drug trial was carried out with
streptomycin over fifty years ago,
but the first trials of treatment in-
cluding a placebo group date back
to the end of the 1700s (Leber
2000). Nowadays clinical drug trials
are regulated by various standards
and regulations (Bardy 2000,
Lääketietokeskus 2000, Lääkelaitos
2001) including ethical principles.
The most important ethical princi-
ples are set out in the Helsinki Dec-
laration of the World Medical Asso-
ciation (WMA 2001) according to
which a new form of treatment
needs to be compared with the best
present method of treatment of the
particular disease. This is not con-
sidered as excluding the use of a
placebo in trials (Idänpää-Heikkilä
2001, International Ethical Guide-
lines for Biomedical Research 2002),
and medical authorities in various
countries actually require placebo-
controlled clinical drug trials in re-
viewing the efficacy of new medical
treatment. It is required by the Eu-
ropean Medicines Agency (EMEA),
for example, that in the most severe
psychiatric conditions – such as
schizophrenia, bipolar affective dis-
order, and severe depression – the
efficacy of a new drug should also
be demonstrated in trials in which
the drug is compared with both the
placebo and the active agent used at
present to treat the particular disor-
der (EMEA 2003). Furthermore, for
some psychiatric disorders there are
no generally accepted current treat-
ment methods available which
would be both adequately effective
and tolerated.
Clinical drug trials in practice
The prerequisites for participation in
a clinical drug trial are that it should
be voluntary and that it should not
involve any significant risks for the
patient. For the latter reason, drug
trials incorporate a detailed list of
excluding factors, the most impor-
tant ones of which for psychiatric
disorders include the risk of suicide
and the inability, associated with
cognitive disorders, to understand
the trial.
The suggestion of participation
in a trial which could probably even
harm the relationship between doc-
tor and patient is considered prob-
lematic, but a recent survey shows
that about three quarters of patients
with even the most severe psychi-
atric disorder, schizophrenia, ap-
proved of clinical drug trials and did
not consider the suggestion to par-
ticipate in one to be harmful to their
relationship with their doctor (Em-
manuel and Miller 2001). Once pa-
tients have given their consent to
participation in a trial they have the
right later at any stage to withdraw
from it without giving a reason and
without any consequent effect of the
withdrawal on their treatment
(Lääketietokeskus 2000). After the
withdrawal the patients will receive
the conventional treatment usually
given for their particular disorder.
The structure of the drug trial
The most important issues under re-
view in a clinical drug trial include
the schedule of emergence of drug
response, the extent of the response,
and the relationship between the size
of the dose and the response, and
between the size of the dose and the
number of adverse effects (Hummer
et al. 2003).
A situation in which the new and
the current conventional treatment
are equally effective is a common
end result in clinical drug trials
The placebo in psychiatric drug trials
Hannu Koponen Ulla Lepola
PROFESSOR SENIOR LECTURER
University of Oulu University of Helsinki
Summary 
Clinical drug trials are regulated by standards and principles with the aim of both safeguarding the
patient safety and ensuring the faultless availability of reliable information about the object of the
survey. In order to achieve the requisite power to detect a possible difference the latter requires sur-
vey groups and methods which are adequately defined and of adequate sample size. The use of a
placebo group in clinical drug trials is as well founded as ever, and is especially important in con-
ditions where the severity is associated with variation in time, or the possibility of a spontaneous
recovery, or there is a significant proportion of subjective experience.
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(Roland and Torgersson 1998). In
this case only the presence of the
placebo group will allow us to judge
whether the therapies compared
with each other are effective at all or
whether any change possibly seen
has been, for example, due to the
patients’ reaction to the trial
arrangements. If the effect of the tri-
al drug proves to be weaker than
that of the control drug, the placebo
group makes it possible to assess
any efficacy there is, in any respect,
in the new drug. But if the efficacy
of neither the trial drug nor the ac-
tive control drug differs from that of
the placebo, the structure and/or the
composition of the patient groups
can be expected to be associated
with some essential problems, or, al-
ternatively, both drugs are ineffec-
tive. If, on the other hand, the trial
drug and the placebo are equally ef-
fective, and the active control drug
is distinctly more effective than
these, the result can reliably be con-
sidered a negative proof of the effi-
cacy of the new product. It should
be borne in mind, however, that the
difference in efficacy between the
placebo and the active medicinal
substance, according to meta-analy-
ses of antidepressants, for example,
is on average about 25% (Roland
and Torgersson 1998). In this case, a
sufficiently large sample of patients
is required for proof of efficacy.
One of the key factors in ethical
evaluations of trials is, in fact, as-
sessment of the sample size. An in-
adequate sample size may lead to an
incorrect negative result (error of
type II), in which case the difference
between the therapies would not be
seen despite the fact that there is one
in reality. An excessively large sam-
ple size would, on the other hand,
expose patients unnecessarily to a
trial therapy or to a placebo. At the
stage of the trial design, assessment
of not only the chief response para-
meters but also of the trial setting
(e.g. parallel groups or an alternat-
ing trial) and the optimum sample
size is made.
Trials aiming to prove the superi-
ority of a new product without a
placebo group are considered justi-
fied if the extent of the response of
the control product compared with
the placebo is great and proven
without doubt (Khan et al. 2001).
The same prerequisite applies to tri-
als aiming to prove that there is no
difference in efficacy between the
new drug and the drug currently in
use. The use of a placebo is upheld
by a situation where there is a minor
difference in efficacy between the
different therapies, by the inaccura-
cy of the measuring method avail-
able, the variations in severity from
one day to another, and also by the
desire to obtain the results of the
comparison within a short time peri-
od and using as few patients as pos-
sible (Emmanuel and Miller 2001,
International Ethical Guidelines
2002).
The equal efficacy of two prod-
ucts has also been reviewed by com-
paring the response achieved with a
placebo group in previous trials. The
use of control groups of the past is
not considered necessary, however,
because the patient groups in differ-
ent studies and any other treatments
the patients receive usually vary in
many respects and the extent of the
placebo response also varies from
trial to trial (Storosum et al. 1998,
Walsh et al. 2002). 
The above-mentioned circum-
stances have resulted in an increase
in the number of patients participat-
ing in trials, especially during the
last decade and more. Inadequate
sample sizes are nevertheless still
considered a problem in some psy-
chiatric trials (Barbui and Hotopf
2001). In addition to the assessment
of efficacy, a placebo group allows
the assessment of undesirable effects
associated with the drug, because
the patients often also exhibit symp-
toms caused by the disorder under
examination or by other illnesses or
medical therapies.
Placebo effect
The placebo response refers to the
change in situation of patients in the
placebo group during the course of
the trial. Even though a placebo is
defined as an ineffective treatment
pharmacologically, the symptoms of
the placebo patients also often vary,
for example, during the trial due to
the trial arrangements (regularity of
the attention paid to the symptoms,
and evaluation of their severity) and
due to the variable periodicity of
symptoms occurring in many psychi-
atric and somatic disorders (Puusti-
nen and Louhiala 2002). The place-
bo response is also affected if the tri-
al situation is misinterpreted as a
treatment situation. The researcher’s
own expectations for the efficacy of
the treatment may also influence the
recovery. The patient’s own expecta-
tions and desire to please the re-
searcher may increase the placebo
response (Cutler et al. 1996).
The prevalence of the placebo re-
sponse may vary between the differ-
ent patient groups depending on the
duration of the disorder, the sub-
group to which it may belong, any
concomitant illnesses, genetic back-
ground and the number of previous
phases of symptoms and the degree
of recovery from them. The placebo
response may also occur more easily
in patients with mild symptoms, and
successful randomisation should
therefore be especially focused on
(Greist et al. 2002).
An extensive placebo response
may lead to a situation where the re-
sponse to the new and the conven-
tional medical treatment is at a level
equal to that of the placebo group.
Attempts have been made to reduce
the placebo response by introducing
a short placebo period of approxi-
mately 1 week at the start of treat-
ment in all patients to exclude the
patients with a placebo response
from the trial. This traditional
method has not, however, been
found to have an effect on the ex-
tent of the placebo response
(Schatzberg and Kramer 2000). Ef-
forts have been made to assess the
extent of the placebo response by
studying the emergence of the re-
sponse, since the placebo response
usually emerges quickly and is tran-
sient compared with the drug re-
sponse, which develops more slowly
but is of a more permanent nature.
The placebo response in psy-
chosis has been considered to be
lower, whereas in anxiety disorders
it has been significantly higher. The
placebo has been found to decrease
the anticipatory anxiety of patients
with panic disorder as effectively as
an active medication does, but there
is a variation in the degree of reduc-
tion in the number of panic attacks
(Schatzberg and Kramer 2000). Pa-
tients with anxiety disorders may be
affected by the trial arrangements
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more than others, and faced with
the fear of social situations the con-
ditioning associated with appoint-
ments may decrease the symptoms.
On the one hand, however, in severe
obsessive-compulsive disorders the
placebo response has been sparse,
and on the other hand the efficacy
of antidepressant therapies given in
several studies on antidepressants
has not differed from that of the
placebo. The placebo response is
therefore not categorically associat-
ed with the severity of the disorder.
An account of the prevalence of
placebo response in some psychiatric
disorders is given in Table.
Potential risks associated with
the use of a placebo
The practice of using patient groups
receiving a placebo product has been
criticised from the ethical and clini-
co-methodological viewpoint. It has
been suggested that the inclusion in
a placebo group would be associated
with significant risks to the patient’s
health. In about one in every three
studies on antidepressants it has not
been possible to point out the differ-
ence between the placebo and a con-
trol preparation previously found to
be an effective antidepressant agent.
It has consequently been suggested
that placebo-controlled clinical drug
trials actually have limited possibili-
ties for producing new information
(Mattocs and Horwitz 2001). The
investigations also show that the ef-
fects associated with trial arrange-
ments may be effective even without
the medication.
Psychiatric disorders are known
to be associated with the increased
risk of suicide (Kasper et al. 1996,
Harris and Barraclough 1998). One
of the key arguments against place-
bo-controlled drug trials brought
forward in discussions on the ethics
of using placebo has in fact been
that the inclusion in a placebo group
increases the risk of suicide in the
patients. The risk has in recent years
been reviewed in patients participat-
ing in drug trials relative to schizo-
phrenia and severe depression. In
the meta-analysis of patients of the
placebo group based on a schizo-
phrenia survey by Storosum and co-
workers (Storosum et al. 2003), only
one patient committed suicide, and
according to the researchers’ results
there was no difference in the risk of
suicide between the placebo group
and the group receiving the active
medical treatment. A meta-analysis
of antipsychotic drug trials carried
out with four different molecules
(quetiapine, clozapine, olanzapine
and risperidone) and submitted to
the US drug authorities during
1987–1997 arrived at the same con-
clusion (Khan et al. 2001).
Similar observations have been
made in studies on severe depression
(Khan and Warner 2000). A meta-
analysis of seven different antide-
pressants, based on the experiences
of nearly 20,000 patients participat-
ing in the analysis, related to an
equal number of suicide attempts
and suicides in both the active con-
trol or trial drug group and the
placebo group. In a later survey car-
ried out with a higher number of pa-
tients, the suicidal behaviour of pa-
tients participating in antidepressant
drug trials did not differ from that
of other patients suffering from se-
vere depression (Khan et al. 2003).
Based on the above results, it could
be judged that patients with in-
creased risk of suicide can, under
present trial arrangements, be ex-
cluded from the trials. Nevertheless,
meta-analyses contain factors of un-
certainty, and even though the ex-
clusion criteria appear to work in
this respect, any suicidal thoughts or
risk of suicidal behaviour of the pa-
tients are very closely monitored
during the trials (Suokas and Suomi-
nen 2002).
Another argument against trials
containing a placebo group has been
that the patient’s disorder is compli-
cated by the absence of the active
medical treatment. Drug trials rela-
tive to psychiatric disorders are usu-
ally of a short duration, lasting for
6-8 weeks on average, which does
not delay the start of the treatment
significantly (Quitkin 1999). The re-
searcher may also withdraw the pa-
tient from the trial if the patient’s
condition or safety of treatment so
requires. Antipsychotic therapy is al-
ways only a part of the treatment of
psychiatric disorders and some of
them can be successfully treated
even without any drugs.
Conclusion
Placebo-controlled clinical drug tri-
als are still considered admissible
provided that the survey design is
scientifically motivated. In a good
survey design the variables affecting
the result and the exclusion criteria
have been carefully chosen and con-
sideration given to the statistical as-
pects. The information on the effica-
cy of drug products given by the
meta-analyses widely in use nowa-
days is more accurate than before
and makes it possible to judge more
accurately the required size of the
trial groups. In addition to the
method of using direct placebo-con-
trol, an increasing number of other
survey frames are used nowadays
and will be used in future where the
method of placebo-control is com-
bined with another form of analysis.
This would, for example, allow pa-
tients randomised to a placebo
group but unable to benefit from the
treatment to be later randomised to
other treatment groups.
The frequency of  placebo response after  di f ferent  metaanalysis  
(Storosum et al. 1998, Cutler et al. 1996, Schatzberg och Kramer 2000, Keck et al.
2000a, Keck et al. 2000b)
Disorder Frequency of  placebo response
- manic phase in bipolar disorder 11–43 %
- depressive phase in bipolar disorder 13–38 %
- severe depression 23–70 %
- schizophrenia 6–43 %
- panic syndrome ca. 50 %
- social fobia 7–43 %
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The National Agency for Medicines
in Finland has been following the
market availability of the actual
medicinal products since the mid-
1980s, and with the help of the pre-
sent marketing authorisation data
the packages have been under scruti-
ny since 1997. Information about the
availability of drugs on the market
was supplemented in the summer of
2004 by comparing the information
in the marketing authorisation data
base with the information in the
drug sales register.
During this autumn the NAM
will introduce a free service on its
website, where publicly available in-
formation on both human and veteri-
nary drugs can be searched for
(www.nam.fi/ ). The service will cover both drugs with currently valid marketing authorisations and drugs with can-
celled authorisations and which have been withdrawn from the market. The service will also provide information on
whether a certain drug with a marketing authorisation is for sale or not. It is therefore necessary that the marketing
authorisation holders inform the National Agency for Medicines of the introduction on to the market of their drugs.
According to the marketing authorisation data system maintained by the Agency, about a third of the medicinal
products with valid marketing authorisation are not available on the market. The more recent the authorisation is, the
more likely it is that it has not yet been introduced on to the market (Fig. 1). The number of valid marketing authori-
sations with the authorisation granted three years ago (see p. 52 Editorial) is about 4,170.  About 700 of these medic-
inal products (about 17%) are not on the
market in Finland. About 15–20% of these
700 products may have been available on
the market earlier, but the packages are not
available at present.
These 3-year-old marketing authorisa-
tions (4,170 of them) are divided into cate-
gories according to the marketing authori-
sation process as shown (Fig. 2). Of the
medicinal products authorised via the cen-
tralised procedure only 48% have been in-
troduced on to the market in Finland, and
of those authorised via the mutual recogni-
tion procedure, in which Finland is the ref-
erence member state, only 46% are on the
market. In comparison, 94% of medicinal
products authorised via the national proce-
dure are available on the market in Finland.
Translation Mervi Moisander
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Accurate information on the availability of drugs
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Fig.  2.   Marketing authorisat ions granted before 1 .9.2001 com-
pared with the medicinal  products introduced on to market  be-
fore 1 .9.2004
Fig.  1 .  The avai labi l i ty  of  medicinal  products by the year  when the au-
thorisat ion was granted
